NEW YORK – Roche announced Thursday its Cobas EGFR Mutation Test v2 received approval from the US Food and Drug Administration of expanded claims as a companion diagnostic for non-small cell lung cancer therapies.
NEW YORK – Roche announced Thursday its Cobas EGFR Mutation Test v2 received approval from the US Food and Drug Administration of expanded claims as a companion diagnostic for non-small cell lung cancer therapies.
...and receive Daily News bulletins.
Already have a GenomeWeb or 360Dx account?
Login Now.
Don't have a GenomeWeb or 360Dx account?
Register for Free.